Affimed NV has appointed Leila Alland as chief medical officer to manage the clinical strategy and execution of the company’s NK and T cell therapy programmes for cancer. Dr Alland joins from Tarveda Therapeutics Inc where she was CMO and oversaw the development of clinical compounds to treat solid tumours. Prior to that, she was head of oncology early clinical development at AstraZeneca Plc. Dr Alland served on the faculty at the Albert Einstein College of Medicine in New York City, US where she received the James S. McDonnell Foundation Scholar Award for research.
Affimed announced the appointment on 19 March 2018.
Copyright 2018 Evernow Publishing Ltd.